UNSPSC 51111769: Vinflunine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C45H54F2N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BF646324K, chemically known as 4-deoxy-20,20-difluoro-c-norvincaleukoblastine but generally known as vinflunine, which bears US NIH Compound Identifier 157688. European Medicines Agency schedules Vinflunine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00063MIG. The term VINFLUNINE is an International Non-Proprietary Name.

UNSPSC 51111769 Vinflunine (Commodity) does not map cleanly to the state and local procurement activity tagged under it. The code nominally identifies vinflunine, a specific oncology pharmaceutical, but the recent opportunities posted under this code procure different drugs entirely—Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone—none of which are vinflunine. The mismatch suggests either a cataloging error in the source systems or a use of this code as a catch-all for pharmaceutical procurement generally. State and local governments buying under this UNSPSC label are acquiring antibiotics and emergency-response pharmaceuticals through piggyback consortiums and direct competitive bidding, typically in multi-unit annual volumes with quarterly or as-needed delivery schedules.

Activity spans state health departments and county public-health authorities, with the Illinois Department of Public Health and Seminole County, Florida among recent buyers. The Illinois Department of Public Health awarded a $2.999 million piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with a 12-month initial term and renewal options. Seminole County released an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a July 26, 2023 response deadline. The geographic and issuing-body spread is too narrow in the recent record to characterize with confidence; the code shows minimal recent activity clearly aligned to its nominal scope.